Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases.
Qiuyi ZhangXiaofeng LanJiayi HuangXiaofeng XieLiping ChenLin SongXue BaiXuelian ChenHaiman JingCaiwen DuPublished in: Technology in cancer research & treatment (2024)
Palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer was effective and well-tolerated, even in patients with brain metastases. More benefits were observed in frontline therapy, chemotherapy-naive, and endocrine therapy-sensitive patients with fewer metastatic sites.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- brain metastases
- small cell lung cancer
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- squamous cell carcinoma
- cell therapy
- bone marrow
- hiv infected
- mesenchymal stem cells
- pluripotent stem cells
- locally advanced
- antiretroviral therapy
- smoking cessation